atezolizumab

Details

Files
Generic Name:
atezolizumab
Project Status:
Complete
Therapeutic Area:
Non-small cell lung cancer
Manufacturer:
Hoffmann-La Roche
Brand Name:
Tecentriq
Project Line:
Reimbursement Review
Project Number:
PC0269-000
Tumour Type:
Lung
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Atezolizumab as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with stage II-IIIA (according to AJCC/UICC 7th edition) non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on 50% of tumour cells (TCs) and do not have epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.
Submission Type:
Initial
Companion Diagnostics:
Yes
Fee Schedule:
Schedule A
Indications:
​Atezolizumab as monotherapy for adjuvant treatment following resection and platinum-based chemotherapy for patients with non-small cell lung cancer (NSCLC) whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TCs).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openJanuary 26, 2022
Call for patient/clinician input closedMarch 18, 2022
Clarification:

- Patient input submission received from Lung Cancer Canada and Lung Health Foundation / The Ontario Lung Association

Submission receivedFebruary 24, 2022
Submission acceptedMarch 10, 2022
Review initiatedMarch 11, 2022
Draft CADTH review report(s) provided to sponsor for commentMay 26, 2022
Deadline for sponsors commentsJune 06, 2022
CADTH review report(s) and responses to comments provided to sponsorJune 30, 2022
Expert committee meeting (initial)July 13, 2022
Draft recommendation issued to sponsorJuly 26, 2022
Draft recommendation posted for stakeholder feedbackAugust 04, 2022
End of feedback periodAugust 18, 2022
Final recommendation issued to sponsor and drug plansSeptember 01, 2022
Final recommendation postedSeptember 20, 2022
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)September 16, 2022
CADTH review report(s) postedDecember 15, 2022